Ερευνητικές ομάδες - Stabilis 4.0

Τελευταία ενημέρωση :
19/11/2024

Ερευνητικές ομάδες - Quality Evaluation Team, Samsung Bioepis Co

pdf

Ιαπωνία

φαρμακευτικό εργαστήριο

Quality Evaluation Team, Samsung Bioepis Co

Incheon

Email

sujin8171.park@samsung.com

Βιβλιογραφία

Βιβλιογραφία

(4)

1

In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D - 2023 - ;23,4:363 - 375

2

Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. (sujin8171.park@samsung.com)
Adv Ther - 2020 - ; 37: 4308–4324.

3

Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther - 2019 -

4

Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther - 2019 - 36:442–450

Καταστάσεις

μόρια που μελετήθηκαν

(4)

		Adalimumab
		Bevacizumab
		Eculizumab
		Trastuzumab

Mentions Légales